image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 25.38
0.237 %
$ 144 B
Market Cap
18.39
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PFE stock under the worst case scenario is HIDDEN Compared to the current market price of 25.4 USD, Pfizer Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PFE stock under the base case scenario is HIDDEN Compared to the current market price of 25.4 USD, Pfizer Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one PFE stock under the best case scenario is HIDDEN Compared to the current market price of 25.4 USD, Pfizer Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PFE

image
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
63.6 B REVENUE
8.77%
14.9 B OPERATING INCOME
344.72%
8.05 B NET INCOME
270.67%
12.7 B OPERATING CASH FLOW
46.48%
2.65 B INVESTING CASH FLOW
108.22%
-17.1 B FINANCING CASH FLOW
-65.76%
13.7 B REVENUE
-22.79%
4.42 B OPERATING INCOME
38.85%
2.97 B NET INCOME
623.36%
2.34 B OPERATING CASH FLOW
-65.26%
3.27 B INVESTING CASH FLOW
301.73%
-5.23 B FINANCING CASH FLOW
-2.21%
Balance Sheet Pfizer Inc.
image
Current Assets 50.4 B
Cash & Short-Term Investments 20.5 B
Receivables 14.8 B
Other Current Assets 15.1 B
Non-Current Assets 163 B
Long-Term Investments 2.23 B
PP&E 18.4 B
Other Non-Current Assets 142 B
9.60 %6.92 %7.08 %8.62 %66.74 %Total Assets$213.4b
Current Liabilities 43 B
Accounts Payable 5.63 B
Short-Term Debt 6.95 B
Other Current Liabilities 30.4 B
Non-Current Liabilities 81.9 B
Long-Term Debt 56.7 B
Other Non-Current Liabilities 25.2 B
4.51 %5.56 %24.35 %45.40 %20.18 %Total Liabilities$124.9b
EFFICIENCY
Earnings Waterfall Pfizer Inc.
image
Revenue 63.6 B
Cost Of Revenue 16.4 B
Gross Profit 47.2 B
Operating Expenses 25.6 B
Operating Income 14.9 B
Other Expenses 6.89 B
Net Income 8.05 B
70b70b60b60b50b50b40b40b30b30b20b20b10b10b0064b(16b)47b(26b)15b(7b)8bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.19% GROSS MARGIN
74.19%
23.48% OPERATING MARGIN
23.48%
12.62% NET MARGIN
12.62%
9.11% ROE
9.11%
3.76% ROA
3.76%
8.45% ROIC
8.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pfizer Inc.
image
30b30b25b25b20b20b15b15b10b10b5b5b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 8.05 B
Depreciation & Amortization 7.01 B
Capital Expenditures -2.91 B
Stock-Based Compensation 877 M
Change in Working Capital -3.07 B
Others 891 M
Free Cash Flow 9.84 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pfizer Inc.
image
Wall Street analysts predict an average 1-year price target for PFE of $31.9 , with forecasts ranging from a low of $24 to a high of $36 .
PFE Lowest Price Target Wall Street Target
24 USD -5.44%
PFE Average Price Target Wall Street Target
31.9 USD 25.65%
PFE Highest Price Target Wall Street Target
36 USD 41.84%
Price
Max Price Target
Min Price Target
Average Price Target
363634343232303028282626242422222020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
1.69% DIVIDEND YIELD
0.43 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.800001.800001.600001.600001.400001.400001.200001.200001.000001.000000.800000.800000.600000.600000.400000.400000.200000.200000.000000.000000.280.284190.320.340.360.380.390.40.410.420.430.280.284190.320.340.360.380.390.40.410.420.430.280.284190.320.340.360.380.390.40.410.420.430.281.120.284191.140.321.280.341.360.361.440.381.520.391.560.41.600.411.640.421.681.292015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Pfizer Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
64.8 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
148 K USD 1
Bought
0 USD 0
0-3 MONTHS
499 K USD 1
3-6 MONTHS
28.2 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025) This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.3%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 9%. seekingalpha.com - 1 week ago
The Best Dividend Stocks I'd Buy Right Now Savvy investors know not to overlook the power of dividends. And Warren Buffett, arguably the savviest investor of all, appreciates dividends, too. fool.com - 1 week ago
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025) Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%. 247wallst.com - 1 week ago
2 Stocks to Buy With Less Than $50 One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices. fool.com - 1 week ago
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028 Since late 2022, no investment trend has been hotter on Wall Street than the evolution of artificial intelligence (AI). Allowing AI-empowered software and systems to make split-second decisions and grow more efficient at their tasks over time is a game-changing technology that offers utility in most industries around the globe. fool.com - 1 week ago
Stocks At All-Time Highs – Grab Your Gains and Buy These 7% Dividend Gems Investors love dividend stocks, especially those with dependable yields of 7% or higher, because they offer a significant income stream and have substantial total return potential. 247wallst.com - 1 week ago
Pfizer: Options Activity Speaks Bullish The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and innovation, with recent pipeline successes as catalysts. Despite macro risks and ROIC below historical averages, PFE stock's 52% upside to fair value and compelling yield make it a rare value opportunity. seekingalpha.com - 1 week ago
Pfizer Trades Above 50-Day Average for a Month: Time to Buy? PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks. zacks.com - 1 week ago
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. benzinga.com - 1 week ago
Is Pfizer Stock a Yield Trap? When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options. fool.com - 1 week ago
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July For more than a century, Wall Street has been a bona fide wealth-creating machine. Though other asset classes, including bonds, commodities, and real estate, have also delivered positive long-term returns, none of these other investments has come particularly close to matching the average annual return of stocks over the last 100 years. fool.com - 1 week ago
Pfizer (PFE) Outperforms Broader Market: What You Need to Know In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day. zacks.com - 1 week ago
8. Profile Summary

Pfizer Inc. PFE

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 144 B
Dividend Yield 1.69%
Description Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact 235 East 42nd Street, New York City, NY, 10017 https://www.pfizer.com
IPO Date June 1, 1972
Employees 81000
Officers Dr. Albert Bourla D.V.M., Ph.D. Chairman of the Board & Chief Executive Officer Mr. Douglas M. Lankler Executive Vice President & Chief Legal Officer Ms. Payal Sahni Becher Chief People Experience Officer & Executive Vice President Dr. Chris Boshoff FMedSci, M.D., Ph.D. Chief Scientific Officer and President of Research & Development Ms. Jennifer B. Damico Senior Vice President, Controller & Principal Accounting Officer Ms. Sally M. Susman Executive Vice President & Chief Corporate Affairs Officer Dr. Michael S. Vincent M.D., Ph.D. Senior Vice President and Chief Scientific Officer of Inflammation & Immunology Ms. Lidia L. Fonseca Executive Vice President and Chief Digital & Technology Officer Ms. Francesca M. DeMartino Chief Investor Relations Officer Mr. David M. Denton Chief Financial Officer & Executive Vice President